![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d4/Vaborbactam.svg/640px-Vaborbactam.svg.png&w=640&q=50)
Vaborbactam
Chemical compound / From Wikipedia, the free encyclopedia
Vaborbactam (INN)[1] is a non-β-lactam β-lactamase inhibitor discovered by Rempex Pharmaceuticals, a subsidiary of The Medicines Company. While not effective as an antibiotic by itself, it restores potency to existing antibiotics by inhibiting the β-lactamase enzymes that would otherwise degrade them. When combined with an appropriate antibiotic it can be used for the treatment of gram-negative bacterial infections.[2]
Quick Facts Clinical data, Routes ofadministration ...
![]() | |
Clinical data | |
---|---|
Routes of administration | IV |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.235.136 ![]() |
Chemical and physical data | |
Formula | C12H16BNO5S |
Molar mass | 297.13 g·mol−1 |
3D model (JSmol) | |
| |
|
Close
In the United States, the combination drug meropenem/vaborbactam (Vabomere) is approved by the Food and Drug Administration for complicated urinary tract infections and pyelonephritis.[3]